First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer
François‐Clément Bidard(Inserm), Nicholas C. Turner(Institute of Cancer Research), Sasha McClain(AstraZeneca (Japan)), Kevin Kalinsky(Emory University), Sònia Pernas, Massimo Cristofanilli(Cornell University), X. Cynthia(Washington University in St. Louis), Adam Brufsky(University of Pittsburgh), Cynthia Huang Bartlett(Pfizer (United States)), Kyung Hae Jung(University of Ulsan), Giampaolo Bianchini(Vita-Salute San Raffaele University), Nuri Karadurmuş(Sağlık Bilimleri Üniversitesi), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Teresa Klinowska(AstraZeneca (Singapore)), Erica L. Mayer(Harvard University), Einav Nili Gal‐Yam(Sheba Medical Center), Wei He(Virginia Tech), Shin-Cheh Chen(Chang Gung Memorial Hospital), Peter A. Fasching(Universitätsklinikum Erlangen), Stephen Chia(Universitätsklinikum Erlangen), L. Moreau(Santé Publique France), Yeon Hee Park(Samsung Medical Center), Javier Pascual(Breast Cancer Now), Wolfgang Janni(Universität Ulm), Hiroji Iwata(Aichi Cancer Center)
Cited by 106
Related Papers
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k